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Abstract
Th.e. di.strib.ut!on ..of rhodium in Balb/c mice following intraperitoneal (ip) administration of a solution.o! aoouc o rnoc]ium propionate and sodium isonicotnate has been investigated. The me[a
concentration was determined in blood and in the following organ tissues: brain, heart,, lung, liver,
spleen, kidney, testes, and uterus/ovary, and the rhodium concentration was obtained by
Inductively Coupled Argon Atomic Emission Spectroscopy (ICP-AES). The metal was detected in all
organ tissues examined, mainly in spleen, liver, uterus/ovary and heart. Nine days after the
injection, traces of rhodium were found in the liver and kidneys and, twenty days after the injection,
only in the liver.
INTRODUCTION
Since the introduction of cisplatin into clinical practice against human malignant neoplasms [1],
several metal complexes, including rhodium carboxylates, have been tested for antitumor activity
[2-4]. The rhodium(ll) carboxylates have the common tetrabridged acetate structure with a short Rh-
Rh bond (Figure ), whose axial positions can be readily occupied by Lewis bases [5,6].
Figure 1. General molecular structure of the rhodium(ll) carboxylates with two labile positions (L).
The pharmacological evaluations of rhodium carboxylates (rhodium acetate, propionate and
butyrate), have shown statistically significant activity against Ehrlich ascites carcinoma, melanoma
B16, leukemia P388 and leukemia L1210 [2,7,8]. The activity was found to be in the order: acetate
< propionate < butyrate; rhodium(ll) propionate having a more interesting therapeutic index.
However, the researches involving these complexes have diminished, in part because of the
demonstrated acute toxicity [9,10] as well as the evident difficulty of aqueous solubilization of most
of the compounds synthesized.
Recently, we reported a strategy for turning these compounds more water-soluble, by forming
adducts with isonicotinic acid [11], that allows more appropriate experimental investigation of the
activity of rhodium carboxylates on tumor cells.
As an extension of these studies and as part of the pharmacological evaluation of rhodium(ll)
carboxylates, we have studied the distribution of rhodium in mice Balb/c following the i.p.
administration of the adduct of rhodium(ll) propionate and sodium isonicotinate.
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MATERIALS AND METHODS
Chemicals
The adduct of rhodium(ll) propionate and isonicotinic acid was prepared by the method previously
described [11]. The compound was dissolved in sodium hydrogen carbonate solution immediately
prior to administration.
Tissue distribution studies
Male and female Balb/c mice (15-20 g) were used throughout this study. The animals received
doses of 30 mg/kg (3.5 times DL10 [11]) ip, and were killed serially (3 males and 3 females per time
point) by cervical dislocation. Blood samples were collected immediately by cardiac puncture.
Whole organs or representative tissue samples were removed and weighed, when necessary.
Tissue analysis
The samples were analyzed for their rhodium content using an Inductively Coupled Argon Atomic
Emission Spectrophotometer (model SpectraFlame Modula), using the line emission Rh 343.489
nm. Tissue (up to 50 mg) and blood (up to 0.10 mL) samples were digested in concentrated nitric
acid (2 mL) for 24 h. After tissue digestion, an attempt to clear the solution was made, adding 30%
hydrogen peroxide (200 IL), followed by a gentle heating (30 min). The resultant solution was
completed to 5 mL with distilled water. The method permits estimation of total rhodium metal in
biological samples and no attempt was made to identify the state of the metal ion present. A
calibration curve was obtained using standard solutions in the range of 1.025-1025 Ig/mL. This
method has a detection limit up to 15.2 Ig/L.
Pharmacokinetic analysis
The pattern of compound from the blood or tissue (liver and kidney) is described by a one-
compartment model and the constants determined are shown in Table 2.
RESULTS
The results, presented in Table 1, were obtained by averaging six values obtained for organs of
three males and three females, except those for testes and uterus/ovary that were obtained from
three values. Standard deviations were less than 20% of the means. The tissue distribution of total
rhodium is shown in Table 1.
TABLE 1. Tissue distribution of rhodium in Balb/c mice after intraperitonial administration.
Tissue Rhodium concentrationa
1 h 8 h 24 h 48 h 6 days 9 days 20 days
Blood 40+/-4 42+4 23+2 15.0_+0.5 2.4_+0.2 ND ND
Brain 16+3 9.9+0.4 15+1 9.7+0.3 0.20+0.02 ND ND
Heart 46+3 51 +2 46+2 50+2 11.3+0.8 ND ND
Lung 31+1 32+3 37+2 32+3 3.1+0.4 ND ND
Liver 38+_5 43+4 57+5 51 +2 23+3 16+2 6.5+0.4
Spleen 79+8 96+8 100+6 96+5 9.6_+0.8 ND ND
Kidney 25_+1 29+2 31+1 28+1 8+1 4+2 ND
Testes 32+5 26+5 40+7 28.8+0.6 1.5+0.5 ND ND
Uterus/Ovary 66+6 71+7 58+6 41 +3 7+1 ND ND
a The mean (N =6) rhodium concentrations are expressed in micrograms per milliliter (g/mL) for
blood and micrograms per gram of wet weight (lg/g) for the tissues. Mean :!: SD; ND: not detectable
Spleen, liver and uterus/ovary are the tissues that showed the highest concentrations of rhodium.
The rhodium persisted in the majority of the tissues for at least six days, disappearing after this
period. In liver, the metal remained more than twenty days. Table 1 indicates that the maximal
rhodium concentration in the tissues was reached at 24-48 h, declining after this period.
The blood, liver and kidney rhodium time data were fitted to a one-compartment model and the
results are shown in Table 2. The tissue half-life of rhodium is about 2-fold greater for liver than for
kidney.
DISCUSSION
The interest in the potential antitumor activity of rhodium(ll) carboxylates has gained new strength in
recent years. Several biological studies have been performed in vitro using tumor cell lines [11,12]
and in vivo with mice bearing tumors [10], searching for more effective compounds. However, there
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is surprisingly little information concerning the distribution of these rhodiumcomplexes in the mice
organism. Giraldietal. [13] found that, following administration of bis(cycloocta-l,5-diene)-tx,rt’-
dichlorodirhodium(I) (40 mg/kg) and bis(I,5-hexadiene)-i.t,l.t’-dichlorodirhodium(I) (20 mg/kg)
complexes, rhodium accumulates in liver and spleen after 4 hours.
TABLE 2. Constants and half-lives for rhodium following
a one-compartment pharmacokinetic analysis.
Tissue Pharmacokinetic Parameters
I%1 (h-1)a tl/2(h)b
Blood 0.0206 33.6
Liver 0.0046 149
Kidney 0.0112 62.0
a Elimination constant bTerminal elimination half-life
The results shown in Table indicate that, after ip injection (30 mg/kg), the compound was rapidly
absorbed and reached maximum blood concentration, c.a. 42,ug/mL, within eight hours. In 24-48
hours, all tissues reached maximal rhodium concentrations, with spleen attaining the higher metal
content. After six days, small amounts of rhodium were found only in liver and kidney. After twenty
days, the rhodium content falls to non-detectable levels for all the tissues except the liver.
Comparing our results (Table 2) with those published for cisplatin and carboplatin in mice [14], we
note that the blood half-life time (tl/2) of rhodium (33.6 h) is slightly shorter than that described for
platinum in cisplatin (36.5 h) or carboplatin (49.5 h). Likewise, the t.,2 of rhodium in liver (149 h) is
similar to that for platinum in cisplatin (133 h) and carboplatin (147 h). However, the t.,2 of rhodium in
kidney (62.0 h) is shorter that for platinum in cisplatin (119 h) and carboplatin (94.9 h).
Acknowledgments
The authors aregrateful to the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
(CNPq) and the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) for financial
support and a post-doctoral fellowship (ARS,FAPESP).
REFERENCES
1. Cleare, M.J. Inorg. Per.spect. Biol. Med.. 1977, 1, 19.
2. Bear, J.L., Howard, R.A. and Dennis, A.D. Curt. Chemother. Proc. Int. Congr. Chemother
lOth, 1977, 1978, 2, 1321.
3. Hall, L.M, Speer, R.J. and Ridgway, H.J. J C/in. Hematol. Oncol. 1980, 10, 25.
4. Zyngier, S.B., Kimura, E. and Najjar, R. Braz. J. Med. Biol. Res. 1989, 22, 397.
5. Bear, J.L., Howard, R.A. and Korn, J.E. Inorg. Chim. Acta. 1979, 32, 123.
6. Koh, Y.-B. and Christoph, G.G. Inorg. Chem. 1979, 18, 1122.
7. Erck, A., Rainen, L., Whileyman, J., Chang, I.M., Kimball, A.P. and Bear, J.L. Proc. Soc. Exp.
Biol. Med. 1974, 145, 1278.
8. Howard, R.A., Kimball, A.P. and Bear, J.L. Cancer Res. 1979, 39, 2568.
9. Howard, R.A., Sherwood, E., Erck, A., Kimball, A.P. and Bear, J.L. J Meal. Chem. 1977,
20, 943.
10. Nothenberg, M.S., Zyngier, S.B., Giesbrecht, A.M., Gambaerdella, M.T.P., Santos, R.H.A.,
Kimura, E. and Najjar, R. J. Braz. Chem. Soc. 1994, 5, 23.
11. Souza, A.R. de, Njjar, R., Glikmanas, S., and Zyngier, S.B. J: Inorg. Biochem. 1996, 64, 1.
12. Pruchnik, F. and Dus, D. J. Inor.g. Biochem. 1996, 61, 55.
13. Giraldi, T., Sava, G., Mestroni, G., Zassinovich, G. and Stolfa, D. Chem. Biol./nteract. 1978,
22, 23. 14. Siddik, .H., Jones, M., Boxall, F.E. and Harrap, K.R. Cancer Chemother. Pharmacol. 1988,
21, 19.
Received: December 5, 1996- Accepted" January 7, 1997-
Received in revised camera-ready format" February 17, 1997
41